{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.561","value":"-1.16"},{"groupId":"OG001","spread":"0.386","value":"-0.18"},{"groupId":"OG002","spread":"0.516","value":"-0.97"}]}],"title":"Change from Baseline at Week 1 [N=9; 18; 13]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.638","value":"-0.99"},{"groupId":"OG001","spread":"0.439","value":"-0.42"},{"groupId":"OG002","spread":"0.586","value":"-1.60"}]}],"title":"Change from Baseline at Week 4 [N=9; 18; 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.558","value":"-0.77"},{"groupId":"OG001","spread":"0.396","value":"-0.70"},{"groupId":"OG002","spread":"0.513","value":"-2.31"}]}],"title":"Change from Baseline at Week 8 [N=9; 17; 13]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.528","value":"-0.98"},{"groupId":"OG001","spread":"0.374","value":"-0.91"},{"groupId":"OG002","spread":"0.485","value":"-2.03"}]}],"title":"Change from Baseline at Week 12 [N=9; 17; 13]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.516","value":"-0.96"},{"groupId":"OG001","spread":"0.355","value":"-0.89"},{"groupId":"OG002","spread":"0.474","value":"-1.98"}]}],"title":"Change from Baseline at EOT [N=9; 18; 13]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"The mean number of incontinence episodes (the involuntary leakage of urine) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at Baseline \\& 1 or both at any postbaseline on-treatment visit. The analysis only includes patients with \\>0 incontinence episodes at baseline. End of treatment (EOT) includes patients who didn't complete Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 1, 4, 8 and 12","title":"Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours","type":"SECONDARY","unitOfMeasure":"Incontinence episodes"}